Noteworthy Literature in 2018 for Cardiovascular Anesthesiologists and Intensivists

Abstract

In this article, we present the annual review of the literature relevant for the practice of cardiovascular critical care.

Keywords

literature review 2018 cardiovascular critical care cardiac surgery factor Xa reversal

Get full access to this article

View all access options for this article.

References

Levy

Douketis

Steiner

Goldstein

Milling

TJ.

Prothrombin complex concentrates for perioperative vitamin K antagonist and non-vitamin K anticoagulant reversal. Anesthesiology. 2018;129:1171-1184.

Ovesen

Purrucker

Gludd

Jakobsen

Christensen

Steiner

Prothrombin complex concentrate versus placebo, no intervention, or other interventions in critically bleeding patients associated with oral anticoagulant administration: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Syst Rev. 2018;7:169.

Heo

YA.

Andexanet alfa: first global approval. Drugs. 2018;78:1049-1055.

Connolly

Milling

Jr Eikelboom

et al . Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131-1141.

Andexxa (andexanet alfa) [package insert]. San Francisco, CA: Portola Pharmaceuticals, Inc; 2018.

Witt

Nieuwlaat

Clark

et al . American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018;2:3257-3291.

DeGuzman

Hollenbach

et al . A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-451.

Del Greco

Johnson

. Clinical experience with angiotensin II in the treatment of shock. JAMA. 1961;178:994-999.

Dager

Hellwig

Current knowledge on assessing the effects of and managing bleeding and urgent procedures with direct oral anticoagulants. Am J Health Syst Pharm. 2016;73(10 suppl 2):S14-S26.

10.

Derrick

Anderson

Roland

BJ.

Adjunctive use of a biologic pressor agent, angiotensin, in management of shock. Circulation. 1962;25:263-267.

11.

Bradley

Parker

The hemodynamic effects of angiotonin in normal man. J Clin Invest. 1941;20:715-719.

12.

Chawla

Busse

Brasha-Mitchell

et al . Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534.

13.

Khanna

English

Wang

et al . Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419-430.

14.

Phend

. FDA greenlights vasopressor drug for shock—angiotensin II should be used with antithrombotic. https://www.medpagetoday.com/criticalcare/sepsis/70061. Published December 21, 2017. Accessed November 27, 2018.

15.

Busse

Wang

Chalikonda

et al . Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med. 2017;45:1285-1294.

16.

Rosner

Okusa

MD.

Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1:19-32.

17.

Lagny

Jouret

Koch

et al . Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC Nephrol. 2015;16:76.

18.

Machado

Nakazone

Maia

LN.

Prognostic value of acute kidney injury after cardiac surgery according to kidney disease: improving global outcomes definition and staging (KDIGO) criteria. PLoS One. 2014;9:e98028.

19.

Hobson

Yavas

Segal

et al . Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation. 2009;119:2444-2453.

20.

Husain-Syed

Ferrari

Sharma

et al . Preoperative renal functional reserve predicts risk of acute kidney injury after cardiac operation. Ann Thorac Surg. 2018;105:1094-1101.

21.

Sharma

Zaragoza

Villa

et al . Optimizing a kidney stress test to evaluate renal functional reserve. Clin Nephrol. 2016;86:18-26.

22.

Levey

Stevens

Schmid

et al . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.

23.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1-138.

24.

Husain-Syed

Ferrari

Sharma

et al . Persistent decrease of renal functional reserve in patients after cardiac surgery-associated acute kidney injury despite clinical recovery. Nephrol Dial Transplant. 2019;34:308-317.

25.

Jaber

Paugam

Futier

et al . Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018;392:31-40.

26.

American Society of Health-System Pharmacists. Drug shortages statistics. https://www.ashp.org/login.aspx?returnURL=https%3a%2f%2fwww.ashp.org%2fdrug-shortages%2fshortage-resources%2fdrug-shortages-statistics&SSOCheckOnly=Y. Accessed November 29, 2018.

27.

Griffith

Gross

Sutton

et al . The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. Clin Infect Dis. 2012;54:684-691.

28.

Vail

Gershengorn

Hua

Walkey

Rubenfeld

Wunsch

Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA. 2017;317:1433-1442.

29.

Singleton

MM.

Group purchasing organizations: gaming the system. J Am Phys Surg. 2018;23:38-42.

30.

Scanlon

; Government Accountability Office. Testimony before the Subcommittee on Antitrust, Competition, and Business and Consumer Rights, Committee on the Judiciary, US Senate. Group Purchasing Organizations: pilot study suggests large buying groups do not always offer hospitals lower prices. https://www.gao.gov/assets/90/81813.pdf. Published April 30, 2002. Accessed December 4, 2018.

31.

Bruhn

Fracica

Makary

MA.

Group Purchasing Organizations, health care costs, and drug shortages. JAMA. 2018;320:1859-1860.

32.

Kweder

Dill

: Drug Shortages: The Cycle of Quantity and Quality, Clin Pharm & Therapeutics (2013); 93 3, 245–251.

33.

Kweder

Dill

Drug shortages: the cycle of quantity and quality. Clin Pharmcol Ther. 2013;93:245-251.

34.

Social Security Act Section 1128B(b), 42 U.S. Code § 1320a-7b Criminal penalties for acts involving Federal health care programs. https://www.ssa.gov/OP_Home/ssact/title11/1128B.htm. Accessed April 2, 2019.

35.

The Medicare and Medicaid Patient and Program Protection Act of 1987, Public Law 100-93. Healh Care Financ Rev. 1987;9:107-113.

36.

Institute for Safe Medication Practices. A shortage of everything except errors: harm associated with drug shortages: https://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=20. Published April 19, 2012. Accessed November 29, 2018.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB